One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood.v128.22.2042.2042
Copy DOI Journal: Blood |  Publication Date: Dec 2, 2016 |
 Citations: 9 |
Affiliation: University of California, San Diego, Pharmacyclics (United States), AbbVie (United States), University of Ulm, University of Cologne, St James's University Hospital, Medical University of Silesia, Medical University of Vienna, Janssen (United States), The Ohio State University, Juravinski Cancer Centre, McMaster University, Hofstra University, University of Rochester Medical Center, KU Leuven, The University of Texas MD Anderson Cancer Center, University of California, Irvine, Dokuz Eylül University, Mayo Clinic, Winneshiek Medical Center, Stanford University11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
